Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Comparing PCI and CABG for heart failure patients with low ejection fraction

Official title: CABG or PCI in Patients With Ischemic Cardiomyopathy - A Randomized Registry Clinical Trial

Run by Vastra Gotaland Region · NCT05329285 · Data updated 2026-11-12

This study is testing whether a less invasive heart procedure called PCI is just as safe and effective as traditional heart surgery, CABG, for patients with heart failure and low heart function.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment470 (estimated)
SponsorVastra Gotaland Region
Government
Locations1 site (Gothenburg)
StatusRecruiting
StartedSeptember 14, 2022
Main results expectedDecember 31, 2028
Study endsDecember 31, 2052
Registry record updatedOctober 13, 2026
Trial IDNCT05329285 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and older with symptomatic heart failure classified as NYHA class II-IV and an ejection fraction of 40% or less.

Probably not a fit

Patients who do not have ischemic cardiomyopathy or those with ejection fractions above 40% may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The STICH-SWEDEHEART trial aims to compare the effectiveness of Percutaneous Coronary Intervention (PCI) versus Coronary Artery Bypass Grafting (CABG) in patients suffering from ischemic cardiomyopathy and reduced left ventricular function. This multicenter, open-label, randomized controlled trial will enroll 470 subjects with multi-vessel coronary artery disease and an ejection fraction of 40% or less. The primary objective is to determine if PCI is non-inferior to CABG in preventing serious complications such as death, stroke, or heart failure hospitalization within three years. The study addresses a critical gap in clinical guidance for treating heart failure patients with significant coronary artery disease.

Why it matters

Potential benefit: If successful, this trial could provide clearer guidance on the best revascularization strategy for heart failure patients with low ejection fraction, potentially improving patient outcomes.

How similar studies have gone: Previous studies have shown varying results in comparing PCI and CABG, but this specific focus on heart failure patients with low ejection fraction is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age ≥18 years.
2. Symptomatic HF defined as NYHA HF class II-IV within 1 month of enrolment
3. LVEF ≤ 40% quantified by either echocardiography or gated SPECT ventriculography, or magnetic resonance (MR) or any other recognized assessment of LVEF
4. Meaningful amount of myocardium at risk because of CAD (BCIS myocardial jeopardy score ≥ 6 on a recent (\> 6 months) coronary angiogram);
5. Heart team believes that a meaningful revascularization can be achieved by both PCI or CABG, with complete revascularization defined as residual ischemia in \<10% of the left ventricle
6. Heart team agrees that guideline directed medical therapy (GDMT) has been initiated for ≥1 month in prevalent and newly diagnosed cases. In patients hospitalized with newly diagnosed iLVSD (with or without acute coronary syndrome (ACS)) requiring revascularization before discharge, GDMT needs to be initiated, when possible, in-hospital before randomization, with the expectation that it will be titrated to maximally tolerated doses after revascularization
7. Written informed consent obtained

Exclusion Criteria:

1. Previous randomization in the study
2. Decompensated heart failure requiring inotropic /adrenergic support, invasive or non-invasive ventilation or intra-aortic balloon pump/ventricular assist device therapy less than 48 hours prior to randomization
3. Recent (\<1 month) type 1 myocardial infarction
4. Recent PCI (\<3 months)
5. Valvular heart disease or any other cardiac conditions (e.g. LV aneurysm) requiring surgical repair/replacement
6. Prohibitive bleeding risk or clinical scenario mandating avoidance of long-term dual antiplatelet therapy
7. Expected survival less than 3 years due to non-cardiac illness
8. Circumstances likely to lead to poor treatment compliance
9. Individuals for whom record in public health databases is not accessible (non-eligibility to public health system, parallel healthcare systems
10. Pregnancy or woman of childbearing potential who is not sterilized or using a medically accepted form of contraception

Where it's running

  • Kardiologen
    Gothenburg, Sweden
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.